Capital Fund Management (CFM)
VIR icon

Capital Fund Management (CFM)’s Vir Biotechnology VIR Stock Holding History

Capital Fund Management (CFM)’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-29,260
Closed -$718K – 2109
2023
Q2 		$718K Sell
29,260
-82,639
-74% -$2.08M ﹤0.01% 1498
2023
Q1 		$2.6M Sell
111,899
-225,049
-67% -$5.76M 0.01% 977
2022
Q4 		$8.53M Buy
336,948
+22,317
+7% +$547K 0.06% 458
2022
Q3 		$6.07M Buy
314,631
+86,797
+38% +$2.21M 0.05% 482
2022
Q2 		$5.8M Buy
227,834
+20,919
+10% +$488K 0.05% 474
2022
Q1 		$5.32M Buy
206,915
+97,076
+88% +$2.88M 0.04% 549
2021
Q4 		$4.6M Buy
109,839
+24,861
+29% +$974K 0.03% 673
2021
Q3 		$3.7M Buy
84,978
+22,376
+36% +$969K 0.03% 688
2021
Q2 		$2.96M Buy
+62,602
New +$2.85M 0.02% 784

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Fund Management (CFM)'s VIR Position: Q3 2023 in Review

Capital Fund Management (CFM) sold out of Vir Biotechnology (VIR) in Q3 2023, closing a stake of 29,260 shares — an estimated $718K sold.

Capital Fund Management (CFM) first reported a position in VIR in Q2 2021 and held it in 9 quarters. The position peaked at $8.53M in Q4 2022. 214 funds tracked by Wall St. Rank hold VIR as of Q3 2023.

  • Capital Fund Management (CFM) reported no remaining Vir Biotechnology position as of Q3 2023 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 29,260 Vir Biotechnology shares in Q3 2023, an estimated $718K.
  • Capital Fund Management (CFM) first reported a position in Vir Biotechnology in Q2 2021 and held it in 9 quarters.
  • Capital Fund Management (CFM)'s Vir Biotechnology position peaked at $8.53M in Q4 2022.
  • 214 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2023.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2023, filed 14 Nov 2023.